Skip to main content
P

PATRYS LIMITED — Investor Relations & Filings

Ticker · PAB ISIN · AU000000PAB9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 91 across all filing types
Latest filing 2026-04-19 Capital/Financing Update
Country AU Australia
Listing ASX PAB

About PATRYS LIMITED

https://patrys.com/

Patrys Limited is a biotechnology company focused on the development of novel antibody-based therapies for the treatment of cancer. The company's primary platform is based on Deoxymabs, a suite of antibodies derived from the 3E10 lupus autoantibody. These antibodies possess the unique capability to cross cell membranes and the blood-brain barrier, targeting the cell nucleus to inhibit DNA damage repair mechanisms. Patrys' lead candidates, PAT-DX1 and PAT-DX3, are engineered to exploit the DNA repair deficiencies inherent in many cancer cells, particularly aggressive forms such as glioblastoma and triple-negative breast cancer. Beyond direct anti-tumor activity, the Deoxymab platform is designed for use in synthetic lethality applications and as a delivery vehicle for therapeutic payloads, including nanoparticles and imaging agents, to target primary and metastatic tumors.

Recent filings

Filing Released Lang Actions
$3.2 million Placement to Advance Clinical Trials 3 pages 334.9KB
Capital/Financing Update Classification · 1% confidence The document is a company announcement detailing a placement of new shares to raise A$3.2 million, including issue price, allocation under ASX Listing Rules, attaching options, timetable, and use of funds. This is a fundraising/capital structure update rather than a full financial report or AGM material. It fits the definition of a Capital/Financing Update.
2026-04-19 English
Proposed issue of securities - PAB 9 pages 31.4KB
Share Issue/Capital Change Classification · 1% confidence The document is an Appendix 3B lodged with the ASX that details the proposed issue of new securities (a placement of ordinary shares and attaching options), including the number of securities, issue prices, conditional approvals, timetable, fees and uses of proceeds. This is an announcement of a new share issue under the ASX Listing Rules. Therefore, it falls under the category for share issues and capital changes (Code: SHA).
2026-04-19 English
Trading Halt 2 pages 349.4KB
Regulatory Filings Classification · 1% confidence The document is an ASX market announcement requesting a trading halt under ASX Listing Rule 17.1, with no substantive details on financial results, capital raising terms, or other specific categories. It is a general regulatory announcement (fallback) rather than a report, capital financing update, or other specialized filing. Therefore, it fits the ‘Regulatory Filings’ category (RNS).
2026-04-15 English
Investor Presentation - Broker Meets Biotech 14 pages 1.3MB
Regulatory Filings
2026-03-30 English
Notification of cessation of securities - PAB 4 pages 14.7KB
Regulatory Filings
2026-03-17 English
Change of Share Registry Details 1 page 145.5KB
Regulatory Filings
2026-03-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.